Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706369 | 0.97 | MEN1 (0.58) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2639369 | 0.97 | MEN1 (0.58) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL15222431 | 0.97 | MEN1 (0.58) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL17971072 | 0.97 | MEN1 (0.58) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL15222429 | 0.97 | MEN1 (0.58) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL133695 | 0.85 | HRH3 (0.41) | TSHRHRH3 | |
| SCHEMBL14190949 | 0.84 | TSHR (0.54) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL12561571 | 0.84 | TSHR (0.42) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL22703312 | 0.83 | TSHR (0.43) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL19668069 | 0.82 | TSHR (0.52) | TSHRMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346965-A1 | ENEDIYNE CONJUGATES | SYNAFFIX B.V. (NL) | 2023-11-02 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230250237-A1 | POLYORGANOSILOXANE, POLYORGANOSILOXANE COMPOSITION, CURED PRODUCT, POLYORGANOSILOXANE-CONTAINING ELECTROLYTIC SOLUTION FOR ELECTROLYTIC CAPACITOR, AND ELECTROLYTIC CAPACITOR USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-08-10 | — | — | US | disclosed |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20200369626-A1 | COMPOSITIONS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR 2 (S1PR2) BINDING AGENTS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| US-20180162829-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | CORSAIR PHARMA INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-20180117216-A1 | MATERIALS WITH IMPROVED PROPERTIES | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-05-03 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| WO-2003043975-A1 | AMINE 1,2- AND 1,3-DIOL COMPOUNDS AND THEIR USE FOR TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-6204222-B1 | SUITABLE AS HERBICIDES AND FOR DESICCATION/DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-20 | — | — | US | disclosed |
| EP-0637298-B1 | SUBSTITUTED CYCLOHEXENE-1,2-BICARBOXYLIC ACID DERIVATIVES AND RAW MATERIALS FOR PRODUCING THEM | BASF AG (DE) | 1999-03-31 | — | — | EP | disclosed |
| US-5817603-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | disclosed |
| US-5602074-A | HERBICIDES; PLANT DESICCATION, DEFOLIATION | BASF AKTIENGESELLSCHAFT (DE) | 1997-02-11 | — | — | US | disclosed |
| EP-0641321-A1 | SUBSTITUTED ISOINDOLONES | BASF Aktiengesellschaft (DE) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993024456-A1 | SUBSTITUTED ISOINDOLONES | BASF AKTIENGESELLSCHAFT (DE) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993022280-A1 | SUBSTITUTED CYCLOHEXENE-1,2-BICARBOXYLIC ACID DERIVATIVES AND RAW MATERIALS FOR PRODUCING THEM | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | TSHR 4221/4885MAPK1 76/4885MEN1 983/4885 |
| US-20230346965-A1 | ENEDIYNE CONJUGATES | ENY2, ZYX, TPD52L2 | TSHR 1632/4885MAPK1 3412/4885MEN1 888/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | TSHR 2473/4885MAPK1 3602/4885MEN1 1237/4885 |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | ZC3HAV1, TYMP, ZC3HAV1L | TSHR 4170/4885MAPK1 1374/4885MEN1 1512/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | TSHR 3560/4885MAPK1 113/4885MEN1 1241/4885 |
| US-20200369626-A1 | COMPOSITIONS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR 2 (S1PR2) BINDING AGENTS AND USES THEREOF | S1PR2, S1PR1, S1PR3 | TSHR 537/4885MAPK1 3254/4885MEN1 599/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | TSHR 209/4885MAPK1 2194/4885MEN1 1041/4885 |
| US-20180162829-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | TSHR 927/4885MAPK1 1994/4885MEN1 473/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | TSHR 2473/4885MAPK1 3602/4885MEN1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.